PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known Application Number INFORMATION DISCLOSURE STATEMENT April 16, 2003 **BY APPLICANT** First Named Inventor SEP 0 2 2005 Group Art Unit (use as many sheets as necessary) **Examiner Name** of 1 Attorney Docket Number U.S. PATENT DOCUMENTS Document Number Name of Patentee or Applicant of Pages, Columns, Lines, Where Relevant Publication Date Cited Document Examine r Initiats \* MM-DD-YYYY Passages or Relevant Cite No.1 Number - Kind Code<sup>2</sup> (if Figures Appear known) /JG/ 6.384.077 May 7, 2002 Peet, et al. /JG/ Peet, et al. US 2002/0077361 A1 June 20, 2002 FOREIGN PATENT DOCUMENTS Pages, Columns, Foreign Patent Document Lines, Where Name of Patentee or Relevant Examiner Publication Date Applicant of Cited Cite No.1 Country Code3 - Number4 - Kind Code5 (if Passages or Initials\* MM-DD-YYYY Document Relevant Figures known) T<sup>6</sup> Appear The General /JG/ EP 0 614 977 A2 3/7/1994 Hospital Corporation 4/1/1999 McGill University WO 99/15639 8/3/2000 Laxdale Limited WO 00/44361 Nova-Neuron Inc. 4/12/2001 WO 01/24781 A2 OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of T $^{2}$ the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Cite Examiner No.1 number(s), publisher, city and/or country where published. Initials MARTHA A. NANCE, M.D. "Clinical Aspects of CAG Repeat Diseases," Brain Pathology 7:881-900 (1997) NINA WILLUMSEN, ET AL. "On the effect of 2-deuterium-and 2-methyleicosapentaenoic acid derivatives on triglycerides, peroxisomal &-oxidation and platelet aggregation in rats," Biochimics et Biophysics Acts 1369 (1998) 193-

Examiner Date 10/21/2008 /Jeanine Goldberg/ Considered Signature

Disease 4, 387-397 (1998) Article No. NB980168

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MARK W. BERCHER, ET AL. "Intranuclear Neuronal Inclusion in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation Between the Density of Inclusions and IT15 CAG Triplet Repeat Length," Menrobiolgy of